Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Symtuza Whole, Split, and Crushed Tablets
NCT02984852Phase 1Completed
- Sponsor
- Janssen Scientific Affairs
- Start
- Dec 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (6 arms), sponsored by Janssen Scientific Affairs. Primary endpoints: Maximum Observed Plasma Concentration at Day 4, Area Under the Plasma Concentration Curve from time zero to the last quantifiable concentration at Day 4 and 1 more. Started Dec 2016; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02984852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02984852.